Structure-Guided Identification of Black Cohosh (Actaea racemosa) Tri-terpenoids with In Vitro Activity against Multiple Myeloma.

Johrer, K; Stuppner, H; Greil, R; Cicek, SS. Molecules. 2020 Feb 11;25(4):766. doi: 10.3390/molecules25040766.

Structure-Guided Identification of Black Cohosh (Actaea racemosa) Triterpenoids with In Vitro Activity against Multiple Myeloma.

Johrer, K; Stuppner, H; Greil, R; Cicek, SS. Molecules. 2020 Feb 11;25(4):766. doi: 10.3390/molecules25040766.

Decreased Activity of Circulating Butyrylcholinesterase in Blood Is an Independent Prognostic Marker in Pancreatic Cancer Patients.

Klocker, EV; Barth, DA; Riedl, JM; Prinz, F; Szkandera, J; Schlick, K; Kornprat, P; Lackner, K; Lindenmann, J; Stoger, H; Stotz, M; Gerger, A; Pichler, M. Cancers (Basel). 2020 May 4;12(5):1154. doi: 10.3390/cancers12051154.

IDO in MDS/AML disease progression and its role in resistance to azaci-tidine: a potential new drug target?

Leisch, M; Greil, R; Pleyer, L. Br J Haematol. 2020 Aug;190(3):314-317. doi: 10.1111/bjh.16710. E-pub 2020 May 17.

Quality of life in patients with relapsed/refractory multiple myeloma during ixazomib-thalidomide-dexamethasone induction and ixazomib mainte-nance therapy and comparison to the general population.

Ludwig, H; Ponisch, W; Knop, S; Egle, A; Hinke, A; Schreder, M; Lechner, D; Hajek, R; Gunsilius, E; Petzer, A; Weisel, K; Niederwieser, D; Einsele, H; Willenbacher, W; Rum-pold, H; Pour, L; Jelinek, T; Krenosz, KJ; Meckl, A; Nolte, S; Melchardt, T; Greil, R; Zojer, N. Leuk Lymphoma. 2020 Feb;61(2):377-386. doi: 10.1080/10428194.2019.1666381. E-pub 2019 Sep 26.

Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.

Murthy, RK; Loi, S; Okines, A; Paplomata, E; Hamilton, E; Hurvitz, SA; Lin, NU; Bor-ges, V; Abramson, V; Anders, C; Bedard, PL; Oliveira, M; Jakobsen, E; Bachelot, T; Shachar, SS; Müller, V; Braga, S; Duhoux, FP; Greil, R; Cameron, D; Carey, LA; Curigliano, G; Gelmon, K; Hortobagyi, G; Krop, I; Loibl, S; Pegram, M; Slamon, D; Pa-lanca-Wessels, MC; Walker, L; Feng, W; Winer, EP. N Engl J Med. 2020 Feb 13;382(7):597-609. doi: 10.1056/NEJMoa1914609. Epub 2019 Dec 11.

Neutropenic complications in the PANTHER phase III study of adjuvant tailored dose-dense chemotherapy in early breast cancer.

Papakonstantinou, A; Hedayati, E; Hellstrom, M; Johansson, H; Gnant, M; Steger, G; Greil, R; Untch, M; Moebus, V; Loibl, S; Foukakis, T; Bergh, J; Matikas, A. Acta Oncol. 2020 Jan;59(1):75-81. doi: 10.1080/0284186X.2019.1670353. Epub 2019 Oct 4.

Efficacy and Safety of Tailored and Dose-Dense Adjuvant Chemotherapy and Trastuzumab for Resected HER2-Positive Breast Cancer: Results From the Phase 3 PANTHER Trial.

Papakonstantinou, A; Matikas, A; Bengtsson, NO; Malmstrom, P; Hedayati, E; Steger, G; Untch, M; Hubbert, L; Johansson, H; Hellstrom, M; Gnant, M; Loibl, S; Greil, R; Moebus, V; Foukakis, T; Bergh, J. Cancer. 2020 Mar 15;126(6):1175-1182. doi: 10.1002/cncr.32653. E-pub 2019 Dec 18.

Stromal cell protein kinase C-β inhibition enhances chemosensitivity in B cell malignancies and overcomes drug resistance.

Park, E; Chen, J; Moore, A; Mangolini, M; Santoro, A; Boyd, JR; Schjerven, H; Ecker, V; Buchner, M; Williamson, JC; Lehner, PJ; Gasparoli, L; Williams, O; Bloehdorn, J; Stilgenbauer, S; Leitges, M; Egle, A; Schmidt-Supprian, M; Frietze, S; Ringshausen, I. Sci Transl Med. 2020 Jan 15;12(526):eaax9340. doi: 10.1126/scitranslmed.aax9340.

The AST/ALT (De Ritis) ratio predicts clinical outcome in patients with pancreatic cancer treated with first-line nab-paclitaxel and gemcitabine: post hoc analysis of an Austrian multicenter, noninterventional study.

Riedl, JM; Posch, F; Prager, G; Eisterer, W; Oehler, L; Sliwa, T; Wilthoner, K; Petzer, A; Pichler, P; Hubmann, E; Winder, T; Burgstaller, S; Korger, M; Andel, J; Greil, R; Neumann, HJ; Pecherstorfer, M; Philipp-Abbrederis, K; Djanani, A; Gruenberger, B; Laengle, F; Woll, E; Gerger, A. Ther Adv Med Oncol. 2020 Apr 10;12:1758835919900872. doi: 10.1177/1758835919900872. eCollection 2020.